EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Systemic Antimicrobial Therapy for Diabetic Foot Infections: An Overview of Systematic Reviews

Angela Wright, Stephen Wood, Janath De Silva, J Simon Bell

Antibiotics · 12.06.2023 · 12 (6) · 1041

DOI: 10.3390/antibiotics12061041 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibiotics, online erschienen am 12.06.2023. Verfasst von Angela Wright und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC 3052, Australia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic foot infections (DFIs) are a common complication of diabetes; however, there is clinical uncertainty regarding the optimal antimicrobial selection. The aim of this review was to critically evaluate the recent systematic reviews on the efficacy and safety of systemic (parenteral or oral) antimicrobials for DFI. Medline, Embase, CENTRAL, and CINAHL databases and the PROSPERO register were searched from January 2015 to January 2023. Systematic reviews with or without meta-analyses on systemic antimicrobials for DFI, with outcomes of clinical infection resolution or complications, were included. Of the 413 records identified, 6 systematic reviews of 29 individual studies were included. Heterogeneity of individual studies precluded meta-analysis, except for ertapenem versus piperacillin–tazobactam (RR 1.07, 95% CI [0.96–1.19]) and fluoroquinolones versus piperacillin–tazobactam (RR 1.03, 95% CI [0.89–1.20]) in one review. The application of the AMSTAR-2 tool determined two reviews to be of high quality. There was no statistical difference in the clinical resolution of infections for 24 different antimicrobial regimens (penicillins, cephalosporins, carbapenems, fluoroquinolones, vancomycin, metronidazole, clindamycin, linezolid, daptomycin, and tigecycline). However, tigecycline did not meet non-inferiority against ertapenem ± vancomycin (absolute difference −5.5%, 95% CI [−11.0–0.1]) and was associated with a higher incidence of adverse drug events. There is minimal systematic review evidence to suggest one regimen is superior to another for DFI.

Schlagwörter

Stichwörter der Autor:innen

antimicrobial treatmentdiabetic foot infectiondiabetic foot ulcersystematic reviewsystemic antibiotic treatment

Autor:innen und Institutionen

  • Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC 3052, Australia.
  • Pharmacy Department, Mackay Base Hospital, Mackay, QLD 4740, Australia.
  • Medicine Department, Mackay Base Hospital, Mackay, QLD 4740, Australia.

Zitieren

APA

Wright, A., Wood, S., De Silva, J., & Bell, J. S. (2023). Systemic Antimicrobial Therapy for Diabetic Foot Infections: An Overview of Systematic Reviews. Antibiotics, 12(6), 1041. https://doi.org/10.3390/antibiotics12061041

Vancouver

Wright A, Wood S, De Silva J, Bell JS. Systemic Antimicrobial Therapy for Diabetic Foot Infections: An Overview of Systematic Reviews. Antibiotics. 2023;12(6):1041. doi:10.3390/antibiotics12061041

BibTeX
@article{Wright2023,
  author = {Wright, Angela and Wood, Stephen and De Silva, Janath and Bell, J Simon},
  title = {Systemic Antimicrobial Therapy for Diabetic Foot Infections: An Overview of Systematic Reviews},
  journal = {Antibiotics},
  year = {2023},
  volume = {12},
  number = {6},
  pages = {1041},
  doi = {10.3390/antibiotics12061041}
}
Kostenlos starten →